Anderson believes it would not be surprising if the DOJ waits until the last minute to file that case so that it can see the extent of the damages that accrue to BP in civil suits.
The case, which will be argued before the justices on March 19, is being closely watched because the decision is expected to help clarify the extent to which consumers will be able to file lawsuits against generic drugmakers stemming from alleged harm caused by their medicines.